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1. Introduction
Gastric cancer is the second leading cause of cancer death and the fourth most prevalent ma‐
lignancy worldwide, affecting about one million people per year [1]. In the United States, an
estimated 21,320 cases of gastric cancer (13,020 men and 8,300 women) will be diagnosed
and 10,540 patients will die from this disease in 2012 [2]. The overall incidence of gastric
cancer in the United States has been steadily declined over the past 75 years. Based on Na‐
tional Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) cancer statistic
data from 2005 to 2009, it is estimated approximately 1/114 men and women will be diag‐
nosed with gastric cancer during their life; most people diagnosed with gastric cancer are
over 65 years of age and men have higher gastric cancer incidence and mortality rates than
women [3]. Asians/Pacific Islanders have the highest incidence as well as high mortality
rates. The incidence of gastric cancer is exceptionally high in Northeast Asia, including Ja‐
pan and South Korea, probably as a consequence of genetic factors and active screening pol‐
icies [4]. Central Europe and South America also show a higher incidence rate of gastric
cancer than the United States and Northern and Western European countries [5]. In addition
to the geographic, ethnic, racial and genetic differences on the incidence of gastric cancer,
environmental factors such as a high infection rate of Helicobacter pylori in Northeast Asia,
also play an important role [6].
The significant improvement and widespread use of upper gastrointestinal endoscopy have
led to early detection of gastric cancer. Early gastric cancer represents approximately 20% of
all newly diagnosed cancer in the United States and up to 60% in Japan and South Korea [7,
8]. Marked advances in endoscopic procedures such as endoscopic mucosal resection (EMR)
and submucosal dissection enhance a dramatic clinical therapeutic impact on the mortality
rate and quality of life after procedures. Now gastric cancer is considered as a potentially
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curable cancer at an early stage. Moreover, modern targeted therapies for gastric cancer us‐
ing trastuzumab suggest a promising progress in treatment and clinical outcome even in an
advanced stage.
Data on topographic distribution of esophageal and gastric cancers since 1976 indicate that can‐
cers of distal esophagus, gastroesophageal junction (GEJ), and gastric cardia have been in‐
creased in incidence with the reverse in incidence of the distal gastric cancers [9].  Now,
adenocarcinomas of proximal stomach (upper third) account for approximately 30% of all gas‐
tric cancers and its clinical impact becomes more important. Although active and vivid clinical
trials have been ongoing on to seek effective therapeutic modalities for GEJ and gastric cardia
adenocarcinomas, there has been no universal consensus classification of these disease entities
into one over the other, gastric carcinoma vs. esophageal carcinoma, due to lack of standard def‐
inition of GEJ and cardia as an anatomic site [10]. The International Classification of Diseases
and Siewert classification system have shown different categorizations of the origins of these
tumors into esophageal or gastric cancer. In the recently published seventh edition of the Can‐
cer Staging Manual of the American Joint Commission of Cancer, however, tumors of the GEJ
and gastric cardia are included under the esophageal carcinoma [11]. The debate on this catego‐
rization is still ongoing, especially for general surgeons [12, 13].
2. Adenocarcinoma of gastroesophageal junction
Despite dramatic decrease in incidence of distal gastric cancer with a better clinical out‐
come, the incidence of adenocarcinomas of the distal esophagus, GEJ, and gastric cardia
has been increased from 4% to 10% per year in the United States, predominantly in men
since 1976 [9, 14-16].  In Japan, the proportion of these tumors has also increased among
men over last 15 years [17]. This epidemiologic trend has an important clinical influence
because  adenocarcinomas  of  the  GEJ  and gastric  cardia  showed much worse  prognosis
than that of distal gastric cancer, with 5-year survival rates in the range of 14% to 22%,
and  minimal  chemotherapeutic  response  in  an  advance  stage  [18,  19].  Moreover,  there
has been no established consensus for the classification of these tumors and therapeutic
modalities including lymphadenectomy, the extent of surgical resection, and chemothera‐
py  [20,  21].  In  addition,  some  studies  have  demonstrated  that  adenocarcinomas  of  the
cardia  have  different  clinicopathologic  characteristics  compared  to  adenocarcinomas  of
distal stomach such as a higher male to female ratio, different ethnic background, a his‐
tory of  chronic  heartburn or  duodenal  ulcer,  and association with smoking and alcohol
drinking [22, 23]. Furthermore, adenocarcinoma of the gastric cardia shows a greater ten‐
dency to invade deeply into the gastric wall and frequent lymph node metastasis with a
worse prognosis [24-26].
Although the main cause of the increasing rate of GEJ cancer is controversial, previous stud‐
ies demonstrated that these tumors were significantly associated with symptomatic reflux
disease and suggested that GEJ cancers are more likely arising from the distal esophagus
than from the stomach [27, 28]. In addition to symptomatic reflux disease as a risk factor,
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recent studies from Japan demonstrated that Helicobacter pylori infection appeared to be al‐
so correlated with GEJ cancers in the Helicobacter pylori infection endemic areas [29].
In 1998, Siewert and Stein have proposed the new classification of GEJ cancers based on
their anatomic sites with estimated origins. This system divides these tumors into three
types as follows: type I, distal esophageal adenocarcinoma with the epicenter of the tumor
lying 2.5 cm above the cardia; type II, cardiac adenocarcinoma that the tumor straddles the
GEJ with the epicenter in the region 1 cm above or 2 cm below the cardia (Fig.1); and type
III, subcardiac adenocarcinoma with its epicenter 2-5 cm below the cardia [30].
In the International Classification of Disease recently, however, adenocarcinomas arising in the
distal third of the esophagus and those that straddle the GEJ are grouped with tumors of the
gastric cardia and all these tumors assign under the category of gastric adenocarcinoma [31].
Figure 1. Siewert type II gastroesophageal junction carcinoma. The tumor is ill defined and irregularly elevated (yel‐
low arrow). It involves cardia and distal esophagus, which exactly straddles the gastroesophageal junction.
The  current  7th  edition  of  the  AJCC  TNM  classification  of  malignant  tumors  provided
rules  for  classifying  adenocarcinomas  of  distal  esophagus,  GEJ,  and  gastric  cardia  [11].
According to this system, any tumors with an epicenter within 5 cm of the GEJ and tu‐
mors which extend into the distal  esophagus are to be classified as esophageal  carcino‐
mas and staged as such. It  means that all  other tumors at  the GEJ with an epicenter in
the stomach > 5 cm from the GEJ or those within 5 cm of the GEJ without extension into
the  esophagus are  to  be  classified and staged as  gastric  carcinomas.  Therefore,  most  of
type  II  cardiac  and type  III  subcardiac  adenocarcinomas  by  Siewert  are  now staged  as
esophageal adenocarcinomas (Fig.2). In a recent clinical study, the prevalence and distri‐
bution of  lymph node metastasis  in  patients  with adenocarcinoma of  the distal  esopha‐
gus  and GEJ  cancers  were  similar  after  esophagectomy and there  was  no  difference  in
overall survival or recurrence between these two groups of cancers. Based on this study,
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they reported that an effort  to separate these two groups of the tumors is  not required,
and both are effectively treated with esophagectomy [32]. However, in the series by Ger‐
tler et al, 1141 patients with type II cardiac and type III subcardiac adenocarcinoma were
reclassified  following  the  current  TNM  system  and  compared  two  different  categoriza‐
tion schemes of  cardiac  and subcardiac adenocarcinoma as  esophageal  or  gastric  cancer
and concluded that neither of the two staging systems proved to be clearly superior over
the other  [33].  Thus,  the categorization of  cardiac  and subcardiac adenocarcinoma (type
II and III by Siewert) into esophageal or gastric cancers, respectively or independent dis‐
ease entity needs to be evaluated further in the near future.
Figure 2.  Gastroesophageal junction carcinoma without Barrett’s  esophagus.  Well  differentiated papillary adeno‐
carcinoma infiltrates into the submucosa of the esophagus without evidence of Barrett’s esophagus in the overly‐
ing mucosa.
3. Early gastric carcinoma
3.1. Definition, epidemiology and clinical manifestation
Early gastric carcinoma (EGC) is defined as an invasive adenocarcinoma that involves only
the mucosa or submucosa but not the muscularis propria, independent of lymph node sta‐
tus [34]. The term, EGC, implies not only the limited extent of the disease but also an early
stage in development and a less aggressive neoplasm, which carries an excellent prognosis if
the lesion is completely removed [35]. Nowadays EGC represents approximately 20% of all
newly diagnosed gastric cancers in Western countries, whereas in Northeast Asia (Japan
and Korea), it accounts for over 50% of cases [36]. The difference in incidence between
Northeast Asia and Western countries may be due to a higher prevalence of gastric cancer
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with mass screening test, and widely adapted use of magnifying upper endoscopy with
high-resolution images and chromoendoscopy in Northeast Asia.
Most  patients  with  EGC are  diagnosed  at  a  median  age  of  63  (range  21-89)  years  and
men are affected more than women like other types of gastric cancer (male to female ra‐
tio,  1.4  -  2.4:1)  [37-40].  The  majority  of  patients  with  EGC are  asymptomatic,  but  some
may present with non-specific upper abdominal symptoms such as heartburn or epigas‐
tric pain, so-called dyspeptic symptoms. Weight loss, anorexia, anemia, and hypoalbumi‐
nemia frequently found in patients with advanced gastric cancer are not commonly seen
[41]. Dyspeptic symptoms may occur in up to 40% of the patients with EGC [42]. Some‐
times,  dyspeptic  symptoms  may  be  an  important  clue  for  the  detection  of  EGCs  [39].
However, dyspeptic symptoms related with EGC can be easily masked by the use of an‐
ti-acid drugs such as cimetidine or proton pump inhibitors [43, 44].  Many EGCs are be‐
lieved  to  go  through  a  cycle  consisting  of  ulceration,  followed  by  healing,  and  re-
ulceration [45].  It  suggests that EGC can be partially healed by acid suppression, which
makes difficult to diagnose EGC endoscopically because it mimics a benign peptic ulcer.
Therefore, it is strongly recommended that patients with dyspeptic symptoms should un‐
dergo  an  endoscopic  procedure  with  biopsy  at  least  once  after  the  symptoms  are  re‐
lieved by medication.
EGC  is  regarded  as  an  early  stage  lesion  in  development  that  can  progress  to  an  ad‐
vanced  lesion  [35].  One  prospective  study  on  EGCs  reported  that  the  median  duration
for tumor progression is approximately 3.7 years [46]. However, some EGCs can show a
rapid progression into advanced lesions within a year [47].  Generally,  EGCs are consid‐
ered  to  be  curable  if  the  lesion  is  completely  removed by  endoscopic  resection  or  sur‐
gery.  Most  of  Japanese  series  have  reported  more  than  90% of  5  and  10  year  survival
rates for the patients with EGC [48,  49].  In the Western series,  5-year survival  rates are
variable,  ranging from 68% to 92% [8, 38-40, 50].  EGCs can recur at least 1.9 % of cases
after resection with intervals ranging from 4 months to more than 10 years, with impor‐
tant risk factors for the recurrence including the presence of submucosal invasion, nodal
metastasis, and undifferentiated histology [51].
3.2. Methods for evaluation and staging of EGC
Double-contrast barium upper gastrointestinal series have been used to detect gastric cancer
over the past two decades. However, this study has a limitation to detect small EGCs. For
the lesions of EGC between 5 and 10 mm in diameter, false negative rates are as high as 25%
[52]. Endoscopy is the procedure of choice and should be performed on all patients in whom
the diagnosis of gastric carcinoma is suspected. The endoscopic findings favoring an EGC
associated ulcer include: (1) disruption and clubbing of the surrounding mucosal folds, (2) a
dirty appearance of the surrounding mucosa with adherent mucus or exudates, (3) irregular
margins of the ulcer itself, and (4) island-like residues of intact mucosa within the depressed
area [53].
EGCs can be divided into two subtypes depend on the depth of invasion; intramucosal and
submucosal invasive adenocarcinomas. The status of submucosal invasion in EGC is critical
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for determining the treatment option, surgery vs. endoscopic resection and estimating a risk
of lymph node metastasis that is directly related with a clinical outcome. The 5-year survival
rate for intramucosal invasive EGC is close to 100%, whereas for submucosal invasive EGC
is from 80% to 90% [54, 55]. Therefore, active trials are ongoing in Japan and South Korea to
detect the submucosal invasion in EGCs preoperatively by endoscopy and endoscopic ultra‐
sonography (EUS). Different endoscopic features of intramucosal and submucosal gastric
carcinoma have been investigated for an accurate local staging. Choi et al demonstrated that
intramucosal gastric carcinoma was endoscopically characterized by smooth surface protru‐
sion or depression, erosion, or marginal elevation [56]. In contrast, submucosal gastric carci‐
nomas usually showed distinct endoscopic features with fold convergence (clubbing, fusion,
abrupt cutting) and nodular protrusion/depression [57]. EUS is now widely used for sub‐
staging of EGCs. The overall accuracy rates for staging the depth of invasion of EGCs by en‐
doscopy and EUS were reported 72.2% and 64.8%, respectively [58]. The diagnostic accuracy
of EUS for the depth of invasion can be significantly affected by EGC with undifferentiated
histology and large tumor size [59].
3.3. Gross features
EGCs vary greatly in size raging from microscopic foci to 5 cm, but larger lesions up to
7 cm in diameter are not unusual [38, 60, 61]. These large tumors are typically located in
the  antrum,  around the  angle,  with  predominance  in  the  lesser  curvature  [40,  60].  The
larger  EGCs have a  tendency to  frequently  invade into  the  submucosal  layer,  however,
some studies demonstrated minute EGCs can also invade into the submucosa in 3.3% to
9% of cases [62-64]. EGCs can be found as multiple lesions in the background of intesti‐
nal  metaplasia.  In recent  series,  more than half  of  synchronous gastric  carcinomas were
EGCs,  frequently  in  elderly  patients,  with  the  incidence  of  multiple  synchronous  EGC
ranges from 3.7 % to 7.7% [65, 66]. Oohara et al and Hirota et al demonstrated that syn‐
chronous EGCs are macroscopically flat and small lesions, rarely infiltrate into submuco‐
sa and can be easily missed in preoperative endoscopic or intraoperative evaluation (Fig.
3) [67, 68]. Although it is well known that EGCs rarely metastasize to other organs, Ishi‐
da et  al  reported that 15 (0.6 %) of 2,707 patients with EGC developed liver metastasis,
especially in patients with submucosal invasion, macroscopically elevated type, and with
vascular invasion [69].
The endoscopic or macroscopic classification of gastric cancer established by the Japanese
Gastric  Cancer  Association has  now been accepted worldwide and was  endorsed at  an
international workshop in Paris in 2002 [70]. Particularly, this Japanese classification sys‐
tem based on endoscopic findings of EGCs has been known to be useful to be employed
for the endoscopic  procedures.  EGCs are classified into three different  subtypes accord‐
ing to the morphologic appearance of the lesion on the mucosal surface as follows: type
I  (protruding type,  polypoid tumors),  type  II  (superficial  tumors  with  or  without  mini‐
mal elevation or depression) and, type III (excavated type, tumors with deep depression)
(Fig 4).  Type I  EGC is a tumor that protrudes above the mucosal surface more than 2.5
mm in  height.  Tumors  with  type  II  are  further  subdivided into  three  subtypes  depend
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on the degree of elevation or depression compared to the imaginary horizontal line from
both  ends  of  the  normal  surrounding  mucosa  as  follow:  type  IIa  (superficial  elevated),
type IIb  (superficial  flat),  and type IIc  (superficial  depressed)  (Fig  5).  Type IIa  EGCS is
defined as a lesion that is twice as thick as normal mucosa, but less than or equal to 2.5
mm in height [71].  The distinction between type I  from IIa EGC depends on the extent
of  elevation:  if  the  height  of  the  lesion >  2.5  mm, it  is  regarded as  type I,  and if  ≤  2.5
mm, then it is type IIa [42]. Type IIb lesions represent 58% of minute EGCs measuring <
5 mm in size and are the most difficult type to diagnose endoscopically [52,  72].  There‐
fore, multiple sampling is highly recommended for an accurate histopathologic diagnosis
when  the  lesion  is  suspicious  for  type  IIb  EGC.  Type  III  lesions  are  characterized  by
prominent depression and, ulcer-like excavation (Fig. 6). Many EGCs may have a combi‐
nation  of  different  macroscopic  types,  i.e.,  IIc+III  and IIa+III.  Type  II  EGCs account  for
approximately 80% of cases with type IIc  being the most common macroscopic subtype
[73]. In the series by Craanen et al, types I and IIa lesions are likely to represent the in‐
testinal  type,  whereas diffuse-type EGCs are  likely to  be types of  IIc  or  III  lesions [74].
They also described that specific endoscopic types of EGCs are associated with a risk of
lymph node metastasis, with the lowest rates reported in type I or IIa EGC.
Figure 3. Multiple gastric carcinomas case. An ulceroinfiltrating Bormann type 3 gastric carcinoma is located in the
subcardia (right yellow arrow). In the antrum of lesser curvature, additional small type IIa+IIc early gastric carcinoma
(left yellow arrow) is found. The surrounding gastric mucosa shows diffuse atrophic changes.
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Figure 4. Japanese macroscopic classification of early gastric cancer
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Figure 5. Early gastric cancer. A: EGC type I. The tumor shows a protruding lesion more than 2.5 mm in height. B: EGC
type IIa. The tumor shows a slightly elevated, plaque-like lesion. C: EGC type IIc. A slightly depressed lesion with an
irregular ulcer base mimicking a benign ulcer is seen. D: EGE type IIb+IIc. A combined flat and depressed lesion is ac‐
companied with surrounding nodular gastric mucosa.
Figure 6. EGC type III. An ulcer-like excavated lesion with a prominent depression is present in the body of the lesser
curvature.
3.4. Microscopic features
Histologically,  the  majority  of  EGCs  are  well  differentiated,  tubular  adenocarcinomas.
Most of  the lesions are intestinal  types with predominantly tubular (93%) and papillary
(1%) histology (Fig.7) [73]. Mucinous carcinomas account for 1% of all EGCs. Signet ring
cell  carcinomas and poorly differentiated adenocarcinomas represent 5% and 30% of the
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cases,  and are usually depressed or ulcerated types (types IIc or III)  [73,  75] (Fig 8).  Se‐
vere  atrophic  gastritis  with  diffuse  intestinal  metaplasia  and  pre-existing  adenoma  are
frequently seen in the background of adenocarcinoma. It has been estimated that 10% of
individuals with chronic atrophic gastritis would develop gastric carcinoma in a 15-year
follow-up period [76].
Figure 7. A. The biopsy shows well- differentiated papillary adenocarcinoma with invasion into the lamina propria. B.
The endoscopic submucosal dissection specimen shows that the tumor invades into submucosa.
Figure 8. A. Intramucosal signet ring cell carcinoma with eosinophilic cytoplasm. B. Goblet cells mimicking signet ring
cell carcinoma are found in the same gastrectomy specimen.
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There has been a disagreement between Western and Japanese pathologists in distinguish‐
ing between high grade dysplasia and intramucosal invasive adenocarcinoma of the stom‐
ach. In the United States and Western countries, intramucosal invasive adenocarcinoma of
the stomach has been defined as a lesion that shows clear invasion of the lamina propria in
the form of single cells or small clusters of cells and a diagnosis of high grade dysplasia is
rendered when the lesion shows only cytologic atypia and architectural abnormalities with‐
out clear invasion [77]. However, for Japanese pathologists, a diagnosis of intramucosal in‐
vasive adenocarcinoma has also been made with cytologic atypia and architectural
abnormalities as parts of diagnostic criteria for intramucosal invasive adenocarcinoma in ad‐
dition to intramucosal invasion by tumor [78]. This discrepancy of diagnostic criteria be‐
tween Japanese and Western pathologists had developed a new Vienna classification for
gastric epithelial neoplasia; however, this classification has not been adopted widely.
3.5. Indications for endoscopic resection
In a meta-analysis of 5,265 patients with EGC who underwent gastrectomy with lymph
node dissection, nodal metastasis was observed in only 2.7% of adenocarcinomas with inva‐
sion limited to the mucosa and in 18.6% of EGCs with invasion extending into submucosa
[79]. This seminal paper induced the widespread application of EMR as a first-line therapy
for EGCs meeting several criteria, as underscored by the Japanese Gastric Cancer Associa‐
tion. The current indication of EMR for the treatment of EGCs includes well or moderately
differentiated adenocarcinoma histology. The lesions must be (1) confined to the mucosa; (2)
smaller than or equal to 2 cm for superficially elevated type lesions; (3) smaller than or equal
to 1 cm for the flat and depressed type lesions; (4) no ulcer or ulcer scar; (5) no venous or
lymphatic involvement [80, 81]. However, EMR has a limitation to resect a lesion greater
than 2 cm in size and a relatively high risk of local recurrence up to 35% when resected tis‐
sues are fragmented or margins are not clear [82]. Thus, a new technique of endoscopic sub‐
mucosal dissection (ESD) was recently developed to dissect directly along the deep
submucosal layer, facilitating one-piece resection. After the introduction of ESD, some insti‐
tutions in Japan and Korea have tried to adopt the expanded criteria for ESD. The expanded
criteria for ESD include intramucosal EGS without size limitation for resection (elevated
type), tumor with differentiated type as well as undifferentiated type (≤ 2 cm), and an ulcer‐
ative lesion (≤ 3 cm) [83]. The classic and expanded criteria for EMR and ESD are listed in
table 1. Recently, Hirasawa et al investigated 3,843 patients of solitary undifferentiated type
EGC with status post gastrectomy and lymph node dissection to find clinicopathologic fac‐
tors related with lymph node metastasis [84]. They found that none of 310 intramucosal in‐
vasive EGCs with 2.0 cm or less in size without lymphovascular invasion and ulcer was
associated with lymph node metastasis, which supports the expanded criteria for the endo‐
scopic resection. In addition, in large series by Ahn et al, patients with EGC underwent an
ESD with the extended criteria have shown acceptable clinical outcomes with a relatively
high complete resection (88.4%) and a low local recurrence rate (1.1%) [85]. Careful clinical
and radiographic evaluation using endoscopy and EUS for an accurate local staging and an
appropriate selection of patients are strongly recommended before the application of the ex‐
panded criteria for ESD.
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Intramucosal Carcinoma Submucosal Carcinoma
Ulcer (-) Ulcer (+) Sm1(≤500µm)
Sm2
(>500µm)
Size (mm) ≤ 20 mm > 20 mm ≤ 30 mm > 30 mm ≤ 30 mm Any size
Differentiated carcinoma EMR ESD ESD Surgery ESD Surgery
Undifferentiated carcinoma ESD or Surgeryconsidered Surgery Surgery Surgery Surgery Surgery
EMR indicates endoscopic mucosal resection; ESD, endoscopic submucosal dissection.
Table 1. Endoscopic indication for early gastric carcinoma
3.6. Histologic evaluation of EMR/ESD specimens
Proper handling EMR or ESD specimens is important to get an accurate histopathologic di‐
agnosis. EMR or ESD specimens are evaluated carefully in slices at interval of 2 mm accord‐
ing to the recommendation by Japanese Classification of Gastric Carcinoma [70]. The risk
stratification of lymph node metastasis in EMR or ESD requires careful and precise patho‐
logic examination of the resected tissue. The location, size, gross appearance, histology, de‐
gree of differentiation, microscopic depth of tumor invasion, presence of ulceration,
neoplastic involvement of the lateral and vertical margins, and involvement of the lymphat‐
ics and/or blood vessels in the submucosa must be reported in detail [82]. Invasion to the
lateral margin of EMR or ESD specimens is classified into the following three groups based
on endoscopic and histopathologic evidence: (1) Complete resection; when the lateral mar‐
gin is clear endoscopically and pathologically (minimal probability of local recurrence); (2)
Incomplete resection: when the tumor has definitely invaded the lateral margin endoscopi‐
cally and pathologically (high probability of local recurrence); (3) Not evaluable: when the
tumor has been removed endoscopically, but its lateral margin was not pathologically
evaluable because of a burn effect (burned by diathermic treatment), or mechanical damage,
or when reconstruction was difficult because of piecemeal resection [86]. The presence of
submucosal invasion, positive vertical (deep) margin, and lymphovascular invasion (LVI) in
the EMR or ESD specimens are indications for additional surgical intervention if any of
these three histologic factors are present [87]. If only the lateral mucosal margin is positive
as mapped out by the pathologists, a repeated ESD or ablative therapy of the involved area,
may be attempted [88]. To date, large tumor size (> 3 cm), the presence of LVI, and deep
submucosal invasion (>500 µm) are regarded as the most convincing indicators for a higher
risk of lymph node metastasis in EGCs [89-91]. The recurrence rate of EGCs after EMR is
highly variable, ranging from 2% to 35% in different studies, depending on the accomplish‐
ment of complete resection or not [92-95]. Every study agrees that EMR is associated with a
higher risk of local recurrence compared to ESD due to the piecemeal resection of large le‐
sions. Despite ESD has shown a higher frequency of enbloc and complete resections than
EMR, the local recurrence rate of EGC after ESD still ranges from 1 to 5% [96-98]. Therefore,
surveillance biopsy from post- EMR sites is an important step in the follow up of patients to
evaluate the residual or recurrent tumors. Mitsuhashi et al described pathologic features of
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the post-EMR biopsies which included, (1) architectural changes such as foveolar hyperpla‐
sia, villiform configuration, and lobular glandular proliferation; (2) cytologic changes such
as increased mitoses ( >2 mitoses/foveola), epithelial cytologic atypia, anisonucleosis with or
without microcystic configuration and flattened epithelia, clear cell degeneration, signet ring
cell change, and mucin depletion; (3) stromal changes such as edema of the lamina propria,
fibrinopurulent exudates and granulation tissue related to mucosal ulceration, acute and
chronic inflammation, ecstatic blood vessels, ischemia, and hemorrhage [99]. Although most
of mucosal changes seen in post-EMR biopsies seem to be benign, reactive and non-specific,
among them, three pathologic features including lacy architectural change, clear cell differ‐
entiation, and signet ring cell-like change can create a diagnostic pitfall to pathologists,
which should be distinguished from residual or recurrent adenocarcinoma based on the pri‐
or history of EMR and absence of nuclear atypia
4. Advanced gastric carcinoma
4.1. Clinical manifestation
Men are more frequently affected than women (male: female ratio; 2:1) and the median age
at diagnosis is 70 years of age [3]. No specific physical signs or symptoms for gastric carcino‐
ma exist. The common presenting symptoms and signs in advanced gastric cancer (AGC),
however, include dysphagia, early satiety, epigastric pain, weight loss, anemia, anorexia,
nausea, vomiting and melena. Dysphagia is frequently associated with proximal tumors,
and early satiety can be caused by distal tumors or tumors with linitis plastica appearance
due to gastric outlet obstruction or loss of stomach distensibility [100]. The symptom dura‐
tion is less than 3 months in nearly 40% of patients and longer than 1 year in only 20% [101].
Presenting symptoms and signs in patients with distant metastasis of AGCs may be differ‐
ent from those with AGCs without distant metastasis. These patients may show enlarged
abdominal mass or abdominal swelling due to tumor metastasis to the liver or malignant
peritoneal effusion. Occasionally, the non-regional lymph node metastasis to the supracla‐
vicular area can be superficial and palpable (Virchow’s lymph node). Peritoneal metastatic
spread may be evident as a palpable ovary on pelvic examination (Krukenberg tumor) or
metastasis to the pouch of Douglas on rectal examination (Blumer’s shelf sign) can be detect‐
ed. Vaginal bleeding due to metastasis to the endometrium has been reported in premeno‐
pausal women with AGCs [102]. Patients with AGC may present with paraneoplastic
syndromes such as diffuse seborrheic keratosis, acanthosis nigricans, microangiopathic he‐
molytic anemia, and Trousseau’s syndrome [103]. The overall prognosis of AGCs is poor,
with 5-year survival rate of 20% [104, 105]. Median survival for metastatic or unresectable
disease is approximately 8 to 10 months [106].
4.2. Methods for evaluation and staging
An upper gastrointestinal tract radiography and endoscopy with biopsy have been used as
gold standard tests for the detection of gastric cancer. Advantages of double-contrast upper
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gastrointestinal series are cost-effective, with a low risk of side effects and a high sensitivity
ranging from 85% to 95% for the diagnosis of gastric carcinoma [107]. However, in some cas‐
es, the differentiation between a benign ulcer from a malignant one or gastric lymphoma can
be challenging for radiologists in regard to subtle radiologic findings. Therefore, endoscopy
with histologic confirmation has been a choice of procedure for evaluation of gastric cancer.
The diagnostic accuracy rate of endoscopy with biopsy for upper gastrointestinal cancers is
more than 95% [104, 108]. The diagnostic accuracy of the biopsies usually increases with the
increased numbers of sample taken. Many endoscopists generally take eight to ten biopsies
and a minimum of six biopsies from any lesions is highly recommended with one from each
quadrant and two from the center of the lesion [103]. Biopsy should be taken from the edge
of an ulcerative lesion not from the base because when the biopsy is taken from the base of
the ulcer, only necrotic tissue may be obtained. Gastric forcep biopsy may have limitation
for the proper diagnosis and determination of degree of differentiation in some cases. Takao
et al investigated the discrepancy rates of diagnoses between biopsy samples and resection
specimens and found 1.4 % of adenocarcinoma cases on resection specimens were under- di‐
agnosed as either non-neoplastic lesions or adenomas in biopsies [109]. In regard to the dis‐
crepancy of the degree of differentiation, 97% of differentiated adenocarcinomas and 83% of
undifferentiated adenocarcinoma in biopsies have concordant histology on resection speci‐
mens with a higher discordant rate in undifferentiated carcinoma cases in which undifferen‐
tiated component in biopsies may not represent the degree of differentiation in whole
lesions. Therefore, they suggested endoscopic features should be considered together with
the biopsy diagnosis to determine an appropriate treatment strategy for the lesions. Al‐
though a great effort has been made in search of specific markers that would enable for ear‐
ly detection of gastric carcinoma including CEA, CA19.9, CA72.4, CA50, and pepsinogen in
the serum, and CEA, CA19.9, and fetal sulfoglycoprotein in the gastric juice [103, 110, 111],
no specific biologic markers have been verified for specific gastric cancer markers. Once a
diagnosis of gastric carcinoma has been made, endoscopic ultrasonography and computed
tomography (CT) scan are usually employed for tumor staging. EUS is particularly useful to
estimate the depth of tumor invasion for local staging. Accuracy of EUS for T staging in gas‐
tric carcinoma is approximately 82%, with a sensitivity and specificity of 70% to 100% and
87% to 100%, respectively [112-114]. However, differentiating T2 and T3 gastric carcinoma
may be difficult in some cases due to associated fibrosis in T2 mimicking T3 lesions. Accura‐
cy for T staging of gastric carcinoma by spiral CT is approximately 64%, lower than that of
EUS [115]. Detection of lymph node involvement by spiral CT scan is not reliable with sensi‐
tivity rates ranging from 24% to 43% [116], because lymph node size is not a good parameter
for determining nodal metastasis. CT scan has been used for identifying distant metastasis
to lung, liver, bone, etc. Magnetic Resonance Imaging (MRI) has been known to be almost
comparable to CT scan for staging of AGC and useful to confirm a liver metastasis in equiv‐
ocal cases [117, 118]. However, currently, MRI is limitedly used when the patients have an
allergy to iodine contrast or renal failure due to motion induced artifacts, longer scanning
times and a higher cost than CT scan.
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4.3. Gross features
Approximately 50% of AGCs arise in the distal stomach (the pyloric part of the stomach),
frequently involving the lesser curvature and 16% of AGCs occur in the proximal stomach
(cardia, the upper third of the body and fundus) [17]. AGCs may show various gross ap‐
pearances with different growth patterns. For standardization of the common morphologic
features of AGCs, several classification systems have been proposed. The most widely used
classification for macroscopic appearance of AGC is Bormann classification, dividing AGCs
into four types [119]:
Type 1 Polypoid: Well circumscribed polypoid tumors (Fig. 9).
Type 2 Fungating: Fungating tumors with marked central infiltration (Fig. 10).
Type 3 Ulcerated: Ulcerated tumors with infiltrative margins (Fig. 11).
Type 4 Infiltrating: Diffusely infiltrated tumors (Fig. 12).
In one large series, the percentage of each subtype was type 1 in 7%; type 2 in 36%; type 3 in
25%; and type 4 in 26% [120]. The most common macroscopic type is a type 2 fungating tu‐
mor, which are frequently located in the lesser curvature of antrum. In contrast, polypoid
(type 1) and ulcerated (type 3) types are commonly found in the greater curvature of corpus.
On cut surface, AGC presents as a gray-white to yellow-white solid mass with a firm to hard
consistency and contains areas of hemorrhage and necrosis.
Figure 9. Bormann type 1. Polypoid carcinoma of the stomach is located in the antrum of the lesser curvature. This
elevating solid mass shows focal superficial hemorrhage.
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Figure 10. Bormann type 2. Fungating carcinoma of the stomach with extensive central ulceration involves the an‐
trum.
Figure 11. Bormann type 3. Ulcerated carcinoma of the stomach with infiltrative and heaped-up margins is present in
the lower body of the lesser curvature.
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Figure 12. Bormann type 4. Linitis plastica, diffusely infiltrating carcinoma of the stomach with thickening of gastric
rugae involves the whole stomach.
4.4. Microscopic features and morphologic classifications
Adenocarcinoma accounts for approximately 95% of all malignant gastric neoplasms. Be‐
cause of heterogeneity and complexity in the morphologic characteristics of gastric carcino‐
ma, many histologic classification systems have been proposed. The primary
histopathologic classification used for gastric carcinoma was first described in 1965 by Lau‐
ren [121]. This system provided a general understanding of histogenesis and biology of this
disease. This classification simply divides gastric carcinomas morphologically into two
types: diffuse and intestinal types, which have shown different genetic alterations and bio‐
logic behaviors. This classification has been applied to determine a clinical indication of en‐
doscopic procedure or surgery and has supported unified epidemiologic data of gastric
cancers by researchers.
Intestinal type adenocarcinoma usually arises in the older population with an increased inci‐
dence in men and is frequently associated with chronic atrophic gastritis, intestinal metapla‐
sia and Helicobacter pylori infection in neighboring mucosa [122]. They constitute
approximately 60% of gastric carcinoma in high-risk population and occur frequently in the
antrum as exophytic bulky lesions [123]. These tumors have a tendency to spread hematoge‐
neously and often result in liver metastasis. Helicobacter pylori infection, high-salt diet and
smoking have been recognized as risk factors of intestinal type adenocarcinoma [6]. In re‐
gard to the carcinogenesis of intestinal type gastric carcinoma, Correa et al proposed a mul‐
tistep progression from Helicobacter pylori infection and gastritis to intestinal type gastric
carcinoma [124]. The sequence of changes in the stomach has been proposed that Helico‐
bacter pylori infection or autoimmune gastritis causes atrophic gastritis with intestinal meta‐
plasia, and transforms to dysplasia (adenoma) and further progress to adenocarcinoma.
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Multiple genetic alterations or mutations occur and accumulate in each step of carcinogene‐
sis and result in malignant transformation. However, this hypothetical model only can ap‐
ply to intestinal type adenocarcinoma but not to diffuse type. Microscopically, intestinal
type adenocarcinomas show well developed glandular structures, either with papillary or
tubular component, surrounded by a variable degree of desmoplastic stroma and a mixed
inflammatory infiltration (Fig.13).
In contrast, diffuse type adenocarcinoma frequently occurs in younger patients, with equal
distribution among men and women [122]. It tends to spread by direct tumor extension, re‐
sulting in peritoneal metastasis. Diffuse type adenocarcinoma has been believed to derive de
novo from the peripheral stem cells of gastric gland neck proliferation zone without a recog‐
nizable precursor lesion [125, 126]. Grossly, this tumor frequently shows ulcerations and oc‐
casionally combines with rigid, thickened, leather-bottle appearance of the gastric wall,
called linitis plastica. Microscopically, diffuse type adenocarcinoma is composed of individ‐
ual tumor cells with or without signet ring cell configuration or small clusters of discohesive
pleomorphic cells with little or no gland formation, which commonly deeply invade the full
thickness layers of the gastric wall with desmoplastic reaction. Different clinicopathologic
features of intestinal and diffuse type gastric carcinomas are listed in table 2.
Diffuse  gastric  cancer  rarely  can  be  hereditary  with  an  autosomal  dominant  disorder
which  accounts  for  less  than  1%  of  all  cases  of  gastric  carcinoma  [6].  This  disease  is
caused  by  germline  mutation  of  CDH1  gene  that  encodes  the  cell  adhesion  protein  E-
cadherin,  which plays an essential  role in maintenance of  the epithelial  glandular struc‐
ture  [127].  Diffuse  gastric  carcinoma  is  the  main  cause  of  cancer  mortality  in  patients
with CDH1 gene mutation [128].
Intestinal adenocarcinoma Diffuse adenocarcinoma
Age Old age Young age
Sex M > F M = F
Risk factors Helicobacter pylori infection,high salt diet, and smoking CDH1 gene mutation
Precursors Adenoma or dysplasia Tubule-neck dysplasia orsignet ring cell carcinoma in situ
Surrounding gastric mucosa Atrophic gastritis withintestinal metaplasia
Non-atrophic gastritis or
nonmetaplastic mucosa
Common location Antrum and angulus Corpus and whole stomach
Gross feature Exophytic lesion Ulcerative lesion and linitis plastic
Microscopy Well - developed tubular architecture Discohesive cells or signet ring cells
Routes of cancer dissemination Hematogenous spread Direct invasion into the surrounding organs
Table 2. Clinicopathologic features of intestinal and diffuse types of gastric adenocarcinomas
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Some AGCs may not fit into one of two types clearly, and thus fall into mixed or unclassi‐
fied categories. Mixed type gastric carcinoma accounts for approximately 14% of all gastric
carcinoma [121, 129, 130]. However, there have been only a few studies investigating the
clinicopathologic features of mixed type AGCs. In recent series by Zheng et al, mixed type
adenocarcinomas exhibit larger size, deeper invasion, more frequent local invasion, and
lymph node metastasis compared to intestinal or diffuse type gastric carcinomas [131]. Ko‐
zuki et al also demonstrated a similar result; prominent lymphatic permeation and lymph
node metastasis were more frequently observed in mixed type than the pure type of gastric
carcinoma [132]. These findings suggest that mixed type adenocarcinoma of the stomach
may have more aggressive behavior than two pure types and could be separated as a dis‐
tinct entity.
In 1977, Ming proposed another classification system of gastric carcinoma based on the pat‐
tern of tumor growth and invasiveness as an indicator of biological behavior, expanding vs.
infiltrative type [133]. The expanding type adenocarcinomas grow predominantly by expan‐
sion with a sharply delineated periphery, resulting in a nodular growth of tumor. In con‐
trast, the infiltrative type tumors show diffuse infiltration of tumor cells into the layers of
gastric wall, without forming masses or nodules. There are some overlapping features be‐
tween Lauren and Ming classifications. In most of cases, expanding types of AGC by Ming’s
classification are classified as intestinal types and infiltrative adenocarcinomas are diffuse
types. However, Ming’s classification was made based on the predominant tumor growth
pattern, which limits its value to gastrectomy specimen and cannot be applied to biopsy
specimens [134].
In  1992,  Goseki  et  al  proposed  a  classification  system  of  AGC  based  on  the  degree  of
tubular differentiation and the amount of intracellular mucin production [135].  This sys‐
tem divides AGCs into four groups based on tubular differentiation and mucin produc‐
tion  by  tumor  cells.  Four  grades  of  tumor  were  proposed:  group  I:  well  differentiated
tubules,  intracellular  mucin poor;  group II:  well  differentiated tubules,  intracellular  mu‐
cin  rich;  group  III:  poorly  differentiated  tubules,  intracellular  mucin  poor;  group  IV:
poorly  differentiated  tubules,  intracellular  mucin  rich.  The  prognostic  value  of  Goseki’s
classification has been investigated in only a few studies in patients with AGCs and its
prognostic value remains controversial [136-140 ].
Although the Lauren and other classifications provide a simplified categorization of usual
gastric carcinomas and better understanding of their biology and behavior in large epide‐
miologic studies, they are less useful to apply to a variety of histologic subtypes of gastric
carcinoma for predicting their clinical outcome. World Health Organization (WHO) pro‐
posed a classification to meet this need based on traditional histopathologic features and the
degree of differentiation of gastric carcinoma [141]. Gastric adenocarcinomas are graded like
other glandular neoplasms based on the degree of glandular differentiation into well, mod‐
erately, and poorly differentiated subtypes. Well differentiated carcinoma consists predomi‐
nantly of recognizable, well-formed glands with greater than 95% of glandular component
in a tumor. Poorly differentiated tumors have a little gland formation consisting of pleomor‐
phic tumor cells arranged in solid sheets or clusters with less than 50% of gland formation in
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a tumor. Moderately differentiated tumors are intermediate with 50-95% of gland formation
in a tumor. The degree of differentiation is considered as an important prognostic factor that
is highly associated with the depth of tumor invasion and a risk of lymph node metastasis
[142-144]. WHO classification has been also used for determining the therapeutic options of
patients with gastric carcinoma. The degree of differentiation is one of the important criteria
for performing endoscopic resection.
In WHO classification, gastric carcinomas are divided into five categories based on histopa‐
thologic features including adenocarcinoma, adenosquamous carcinoma, squamous cell car‐
cinoma, undifferentiated carcinoma, and unclassified carcinoma [145]. Adenocarcinomas are
subdivided into papillary, tubular, mucinous and signet ring cell types. Generally, papillary
and tubular variant are classified into intestinal, expanding, or differentiated type, whereas,
mucinous and signet ring cell variants are categorized into diffuse, infiltrative, or undiffer‐
entiated type [146].
Tubular adenocarcinoma consists of tubular-shaped branching glands lined by pseudostrati‐
fied columnar or cuboidal epithelium with elongated hyperchromatic nuclei having coarse
chromatin and occasional mitotic figures (Fig. 14). Acinar structure may be present. The de‐
gree of cytologic atypia varies from low grade to high grade tumors. If tubular adenocarci‐
noma combines with papillary adenocarcinoma component, it is termed as a tubulopapillary
variant.
Figure 13. A. Gastric biopsy shows a well differentiated tubular adenocarcinoma. Adjacent to the carcinoma, regener‐
ative foveolar epitheliums are admixed. B. In high power examination, the anastomosing glands are composed of
atypical cells with vesicular nuclei and prominent nucleoli.
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Figure 14. Tubular adenocarcinoma, well differentiated, in the resected stomach. A. Grossly, the tumor in the high
body of greater curvature is advanced gastric carcinoma mimicking EGC type IIb. B. In the superficial area, the carcino‐
ma mimics regenerative changes due to its bland morphology. C. However, the carcinoma infiltrates into subserosa.
Papillary adenocarcinoma is characterized by elongated finger-like processes that have a fi‐
brovascular connective tissue core in the center and lined by cylindrical or cuboidal cells.
The nuclear cytologic atypia varies from low to high grade. This tumor represents 6% to
11% of all gastric carcinomas [68, 147]. Papillary adenocarcinomas have distinct clinicopa‐
thologic features such as a higher frequency in aged patients, proximal location, and elevat‐
ed macroscopic type [147]. Although papillary adenocarcinoma has been categorized into
differentiated-type adenocarcinoma with low grade malignancy, some studies have shown
that papillary adenocarcinomas of the stomach have a higher frequency of lymph node
metastasis, liver metastasis and poorer surgical outcome compared to other types of gastric
carcinoma [147-149]. Nakashima et al proposed a nuclear grading score for papillary adeno‐
carcinoma of the stomach based on the extent of nuclear pleomorphism and nuclear polarity
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[150]. They also reported that papillary adenocarcinoma with a high nuclear grade is usually
accompanied by more advanced mural invasion, a higher risk of lymph node metastasis,
higher chances of HER2 overexpression, and poorer prognosis. This study suggested that
papillary adenocarcinomas with high nuclear grade of the stomach may be a good therapeu‐
tic candidate for anti-HER2 (trastuzumab) therapy.
Mucinous adenocarcinomas are also referred to as colloid, mucous, and muconodular carci‐
noma. This tumor accounts for 2 % to 6 % of all gastric carcinomas [151]. Mucinous adeno‐
carcinoma is defined as a gastric adenocarcinoma with a substantial amount of extracellular
mucin ( ≥ 50% of tumor volume) within tumors [145]. They may present in one of two forms;
tubular glands with mucus-secreting epithelium surrounding collections of extracellular
mucin and signet ring cells floating in the mucinous lake [152]. Sometimes, the tumor is pre‐
dominantly composed of large acellular mucin pools with a few scattered tubular glands or
signet ring cells (Fig. 15). The clinical outcome and prognosis of mucinous adenocarcinoma
compared to non-mucinous adenocarcinoma is controversial. Some authors reported that
the prognosis of patients with mucinous adenocarcinoma is poorer than that of patients
with non-mucinous adenocarcinoma [153]. However, others demonstrated that the 5-year
survival rates of mucinous and non-mucinous adenocarcinomas are not different when the
tumors are compared stage by stage [152]. A recent study from South Korea reported that in
mucinous gastric carcinomas, tumor size predicted prognosis more accurately than conven‐
tional pT stage (depth of invasion in a study with large number of cases) [154].
Signet ring cell adenocarcinoma of the stomach is characterized by diffuse infiltration of sig‐
net-ring type of tumor cells into the gastric wall. It accounts for 18% of total gastric carcino‐
mas and 13.9% of all AGCs [155]. Histologically, signet ring cell carcinoma is defined as an
adenocarcinoma in which the predominant component (more than 50% of the tumor) con‐
sists of isolated or small groups of malignant cells containing intracytoplasmic mucin with
eccentric nuclei (Fig. 16) [145]. Most signet ring cell carcinomas accompany with marked
desmoplasia within tumor. Signet ring cell carcinomas diffusely infiltrate through the mus‐
cular propria and subserosa with sparing the mucosa and present as firm and non-distensi‐
ble texture, forming leather bottle appearance of stomach (linitis plastica). In these cases,
because a few scattered tumor cells are embedded in the desmoplastic stroma, it is easy to
overlook the presence of malignant cells. Therefore, a careful pathologic examination is
strongly recommended for delineating free margins and depth of tumor invasion during
evaluation for frozen sections as well as permanent sections of gastrectomy specimens. In
problem cases, mucin stains (periodic acid-Schiff, Alcian blue, mucicarmine) and immuno‐
histochemical staining for cytokeratin would be greatly helpful to demonstrate tumor cells.
Li et al reported that the mean tumor size and depth of invasion of signet ring cell carcino‐
ma is slightly larger and deeper than those of non-signet ring cell carcinoma [155]. This tu‐
mor is frequently discovered at an advanced stage such as, stage IIIb and IV, and shows a
higher rate of lymph node metastasis and peritoneal dissemination [155, 156], and is associ‐
ated with the poorer prognosis than other types of adenocarcinoma.
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Figure 15. Mucinous carcinoma. Small clusters or strands of pleomorphic tumor cells containing mucin are present
within mucin pool.
Figure 16. Signet ring cell carcinoma. Signet ring cells showing foamy or pale basophilic abundant cytoplasm and an
eccentrically located nucleus infiltrate the lamina propria.
4.5. Immunohistochemistry
Gastric carcinomas have various amounts of differentiated tumor cells that may express het‐
erogeneous phenotypes of mucin. Mucins are high molecular weight glycoproteins with
complexity and diversity that constitute the major component of the mucus layer within the
gastric epithelium. Up to date, twelve core proteins of human mucin have been described. It
has known that normal human stomach can express MUC1, MUC5AC, and MUC6. MUC1
and MUC5AC are expressed in the superficial foveolar epithelium and mucous neck cells of
both the antrum and corpus, whereas MUC6 is expressed in the pyloric glands of antrum
and the mucous cells of the neck zone of the corpus [157-160]. In contrast, MUC2 is found in
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the Golgi region of foveolar cells in the antrum and predominantly express in the areas of
intestinal metaplasia with vacuolar staining in goblet cells [161, 162]. MUC5B is expressed
only during a brief period of fetal life [163]. Previous studies have shown that MUC5AC ex‐
pression in gastric carcinoma is associated with diffuse type gastric carcinoma and EGC
[164, 165]. The expression of MUC2 is closely correlated with mucinous carcinoma and car‐
dia adenocarcinoma [164]. In additional studies by Pinto-de-Sousa et al, MUC5B was aber‐
rantly expressed in 22% of gastric carcinomas and is associated with differentiation and co-
expression of MUC5AC [166]. Expression of MUC1 is less frequent in adenoma compared to
associated carcinoma [167]. In contrast, MUC2, an intestinal type mucin, was highly ex‐
pressed in the adenomas, but either persisted or decreased after malignant transformation to
adenocarcinomas. These findings suggest that MUC2 expression would be an early event,
while MUC1 expression would be a late event in the carcinogenesis of the stomach [159].
The pattern of mucin expression may help to understand the differentiation pathway of gas‐
tric carcinoma and to predict its biologic behavior. However, it is still controversial whether
expressions of mucin in gastric carcinoma have a prognostic significance or not.
Immunohistochemical staining of cytokeratin 7 and cytokeratin 20 show various expression
in the stomach. Cytokeratin 20 is usually positive for antral epithelium, while cytokeratin 7
highlights the columnar cells of the cardia. It has known that adenocarcinomas of GEJ are
more likely expressed CK7 and distal gastric adenocarcinoma are likely express CK20 [168].
5. Molecular pathology of gastric cancer
Although the carcinogenesis of gastric carcinoma is not clear, a rapid progress in the molec‐
ular biology of cancer helps us to understand a complex process of malignant transforma‐
tion of the gastric epithelium caused by the accumulation of aberrant genetic mutations.
Gastric cancer is a heterogeneous disease with multiple environmental etiologies and alter‐
native pathways of carcinogenesis. Beyond mutations in TP53, alterations in other genes or
pathways account for only small subsets of the disease [169]. Recent studies using next-gen‐
eration sequencing (NGS) have revealed an extensive repertoire of potential cancer-deriving
genes in several cancer types. In stomach, recent exome sequencing data with 22 AGCs
showed that genes involved in chromatin modification to be commonly mutated. A down‐
stream validation study confirmed frequent inactivating mutations or protein deficiency of
ARID1A, which encodes a member of the SWI-SNF chromatin remodeling family, in 83% of
gastric cancers with microsatellite instability (MSI), 73% of those with Epstein-Barr virus
(EBV) infection and 11% of those that were not infected with EBV and microsatellite stable
(MSS). Subsequent exome sequencing data with 15 AGCs showed similar genetic altera‐
tions; frequently mutated genes in the adenocarcinomas included TP53 (73%), PIK3CA
(20%), and ARID1A (20%), and suggested that FAT4 and ARID1A may thus be key tumori‐
genetic events in subset of gastric cancers [170]. In a search for COSMIC (Catalogue Of So‐
matic Mutations in Cancer) data, TP53 mutations is the most frequent mutation followed by
CDH1, ARID1A, MSH6, PIK2CA, CDK2A, APC, FBXW7, KRAS, CTNNB1, PTEN,EGFR,
ERBB2, HRAS and BRAF (Fig.17). Recent high throughput mutation profiling showed simi‐
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lar results [171, 172]. Lee et al first described that mutations of CTNNB1 were significantly
more frequent in EBV-associated gastric carcinoma [171].
Molecular targeted therapies have significantly emerged as an effective treatment and im‐
proved clinical outcomes of many common malignancies, including breast, colorectal, and
lung cancers. Although studies for targeting agents of gastric cancer did not show promis‐
ing results in the past decades, recently, trastuzumab has been approved by US Food and
Drug Administration (FDA) and European Medicine Agency as a first-line therapy in Hu‐
man epidermal growth factor receptor (HER) 2 positive metastatic gastric cancers and GEJ
cancers based on the result of a landmark clinical trial, so called ToGA (Trastuzumab for
Gastric Cancer) study. Currently, many other molecular targeted agents for AGCs are un‐
dergoing clinical trials, including vascular epithelial growth factor (VEGF) inhibitor, other
HER family targeted agents, and etc. In this chapter, we focus on two main targeting agents,
HER2 and VEGF inhibitors, and discuss about their biologic pathways and the results of
clinical trials.
Figure 17. The graph highlights the most significantly mutated genes of gastric cancer from the Cancer Gene Census.
Source: COSMIC: a open information showing somatic mutation related with human cancer, Sanger Institute. http://
www.sanger.ac.uk/genetics/CGP/cosmic/
5.1. Next-generation sequencing of gastric cancer
Recent genome-wide sequencing studies demonstrated that mutations of AT-rich interactive
domain 1A gene (ARIDI1A) were identified in 8-11 % of gastric cancer and frequently in
EBV-positive gastric cancer and MSI-high gastric cancers [170, 173, 174]. ARIDI1A is one of
the subunits of the Switch/Sucrase Non-fermentable (SWI/SNF) chromatin remodeling com‐
plex and involves the regulation of gene expression by binding to AT-rich DNA sequences
[175]. ARIDI1A seems to act like a tumor suppressor gene that involves DNA repair, differ‐
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entiation, development, and has a regulatory role in proliferation [175, 176]. ARIDI1A gene
mutation has been reported in ovarian cancer, predominantly clear and endometrioid sub‐
types, and its rearrangement or deletion were identified in breast and lung cancer cell lines
[176-178]. Recently, Wang et al demonstrated that gastric cancers with ARIDI1A mutation
and loss are a distinct molecular subtype affecting predominantly EBV-positive and MSI-
high gastric cancers, with a better prognosis and different carcinogenesis compared to the
conventional gastric adenocarcinoma. They also demonstrated that ARIDI1A mutations are
reversely associated with mutations of TP53 but concur with PIK3CA mutations. In large
retrospective series by Abe et al, loss of ARIDI1A correlates with larger tumor size, ad‐
vanced invasion depth, lymph node metastasis, and poor prognosis in EBV negative and
MSS gastric cancers [174]. They also suggested that loss of ARIDI1A in EBV-positive gastric
cancer is an early event in carcinogenesis and may precede EBV infection in gastric epithe‐
lial cells.
5.2. Activation of oncogenes
The MET proto-oncogene encodes a tyrosine kinase receptor for the hepatocyte growth fac‐
tor and stimulates mitogenesis, motogenesis, vasculogenesis, and morphogenesis of the cells
[179]. Its overexpression was found in 20% of diffuse and 40% of intestinal type gastric carci‐
nomas. [180-182]. In series of MET gene activation, tumors with c-met protein tended to dis‐
play increased invasiveness and poorly differentiated histology with poor prognosis on
multivariate analysis [183, 184].
Fibroblast growth factor receptors (FGFRs) consist of four different variants and their over‐
expressions are associated with a poorer prognosis in patients with gastric carcinoma [185,
186]. FGFR type II encoding a receptor for keratinocyte growth factor is overexpressed in
33% of diffuse type of AGCs but not in intestinal type carcinomas [186, 187].
Another proto-oncogene, epidermal growth factor receptor genes including HER2 is overex‐
pressed in 20% of intestinal type AGCs but not in diffuse type carcinomas [188]. More de‐
tailed description of ERBB2 is in the next section.
5.3. Inactivation of tumor suppressor genes
The TP53 gene located at 17p13.1 encodes a nuclear protein, which involves cell cycle con‐
trol, DNA repair, cell differentiation and programmed cell death [181]. Mutation or loss of
heterozygosity(LOH) of the TP53 gene has frequently been demonstrated in gastric adeno‐
carcinoma. LOH occurs in 64 % and mutations in approximately 30-50% of gastric carcino‐
mas [189]. Most alterations of the TP53 gene occur in AGCs. In intestinal type gastric
carcinomas, although p53 gene mutations have been identified in 50% of EGCs and seem to
be an early event, there was no proven relationship with tumor stage or progression [190,
191]. However, in diffuse type gastric carcinomas, TP53 gene mutations are significantly in‐
creased in advance stage, indicating the importance of TP53 mutations for tumor stage pro‐
gression.
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Deletions or mutations of the adenomatous polyposis coli (APC) gene located on chromo‐
some 5q21 have been detected in up to one third of gastric carcinoma cases [192]. LOH of
the APC gene occur in approximately 20% of intestinal type gastric carcinomas but not in
diffuse type [193]. However, the frequency of APC gene mutations by histological types has
been controversial and the role of APC gene in the carcinogenesis of gastric carcinoma is not
clear yet compared to colorectal counterpart.
RUNX3 is a recently discovered tumor suppressor gene that is involved in gastric carcino‐
genesis. RUNX3 plays an important role for the suppression of cell proliferation in the gas‐
tric epithelium by inducing p21 expression in cooperation with TGF-β activated SMAD
[194]. Loss of RUNX3 by hypermethylation of the promoter CpG island is observed in
45-65% of gastric carcinomas [195, 196].
Phosphatase and tensin homologue (PTEN) is located on chromosome 10q23.3 and acts as a
plasma membrane lipid phosphatase. PTEN dephosphorylates the second messenger phos‐
phatidylinositol-3,4,5-triphosphate, the product of phosphatidylinositol-3-kinase [197].
PTEN opposes the downstream signaling of phosphatidylinositol-3-kinase/ATP dependent
tyrosine kinase pathway (PI3K) which involves the regulation of apoptosis, cell prolifera‐
tion, migration, angiogenesis, and glucose metabolism [198]. Mina et al reported that PTEN
deletion was found in 8 of 180 gastric cancer cases (4.4%) by fluorescence in-situ hybridiza‐
tion (FISH) and correlated with a higher rate of lymph node metastasis and distant metasta‐
sis indicating an aggressive behavior, which is similar to previous studies [199-201].
Interestingly, Esteva et al reported that PTEN loss in patients with HER2 positive metastatic
breast cancer was significantly associated with a poor response to trastuzumab therapy and
a shorter survival time, suggesting its pivotal role in trastuzumab resistance [202].
5.4. Cell-adhesion molecules and metastasis-related gene
The Wnt signaling pathway plays an essential role in embryonic development and a va‐
riety of processes including cell cycle regulation in differentiated cells. The Wnt signaling
pathway also includes the regulation of β-catenin, which has multiple cellular functions,
from cell surface signaling involving E-cadherin to nuclear translocation [106]. Mutations
in the genes encoding Wnt pathway components  are  associated with various malignan‐
cies  including  tumors  of  gastrointestinal  tract,  in  particular  gastric  cancer.  E-cadherin,
one of the members of the cadherins, acts as an adhesive molecule and plays an impor‐
tant role in growth development and carcinogenesis. E-cadherin gene located at chromo‐
some 16q22 can be inactivated by mutation,  LOH, and hypermethylation [181].  Because
E-cadherin is a components of adhering junctions, the mutations of E-cadherin and relat‐
ed genes result in the dyscohesiveness of tumor cells in the morphology of diffuse type
adenocarcinoma. Decreased expression of E-cadherin is predominantly found in undiffer‐
entiated,  diffuse  type  gastric  carcinomas,  particularly  in  signet  ring  cell  carcinoma  and
associated with  invasiveness  and a  higher  metastatic  potential  of  gastric  carcinomas re‐
sulting  in  a  poorer  prognosis  [203,  204].  Hereditary  diffuse  gastric  cancer  is  caused  by
germline mutations of E-cadherin (CDH1) [205]. Hypermethylation of E-cadherin promot‐
er is another alternative pathway to inactivate E-cadherin gene and found in 83% of cas‐
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es with sporadic diffuse type gastric carcinoma [206]. The Wnt signaling pathway would
be  less  implicated  for  malignant  transformation  of  intestinal  type  adenocarcinoma than
diffuse type.  APC gene mutations and mutations in the exon 3 of  β-catenin lead to de‐
creased phosphorylation of β-catenin and reduced proteolytic degradation of this protein
in  the  Wnt  pathway,  which  result  in  cytosolic  accumulation  of  β-catenin,  its  nuclear
translocation,  and following  malignant  transformation  of  the  gastric  epithelium into  in‐
testinal type gastric carcinoma [207, 208].
5.5. Epigenetic alteration
Aberrant methylation of promoters may lead to the transcriptional silencing of various
genes including E-cadherin, p16, p15, MGMT, CDKN2A, RUNX3 and MLH1. It has been re‐
ported that 40% of gastric carcinomas have CpG island methylation with frequent methyla‐
tion in p16 and MLH1 genes [209]. CpG islands are DNA segments that are at least 0.5 kb in
size, rich in G:C and CpG content, and found in approximately 70% of human gene promot‐
ers as an unmethylated status [210]. Promotor CpG island hypermethylation is found in al‐
most all cancers and involves in carcinogenesis and aging process by affecting on the tumor
related genes and the inactivation of tumor suppressor genes. Kang et al suggested that pro‐
motor CpG island hypermethylation occurs in an early step of the gastric carcinogenesis and
accumulate during malignant transformation [211].
MSI is a DNA mismatch repair deficiency that is one of the pathways of gastric carcinogene‐
sis. MSI has been found in 13%-44% of sporadic gastric carcinomas [212-214]. In gastric car‐
cinomas, MSI is mainly caused by promoter CpG island hypermethylation of MLH1 gene
[215, 216]. MSI due to epigenetic inactivation of MLH1 is found in 15%-39% of sporadic in‐
testinal type carcinomas, 70% of which are associated with loss of MLH1 by hypermethyla‐
tion of the promoter [215, 217]. Gastric carcinomas can be classified as MSI-low and MSI-
high depending on the degree of genomic instability. MSI-high gastric carcinomas have
some distinct clinicopathologic characteristic such as an association with intestinal type, dis‐
tal stomach (antrum), and more favorable prognosis compared to MSS and MSI-low carcino‐
mas [218]. In addition, some studies have shown that MSI-high gastric carcinomas have a
lower risk of lymph node metastasis, near-diploid DNA content and tumoral lymphoid in‐
filtration [219-221]. It is controversial that MSI involves in the early or late stage of gastric
carcinogenesis due to contrary data. Particularly, EBV-positive gastric carcinoma is well
known for global and nonrandom CpG island methylation of the promoter regions of can‐
cer-related genes. Previous studies demonstrated that EBV-positive gastric carcinomas were
strongly associated with CpG-island methylator phenotype and having multiple methyla‐
tion of cancer related genes including genes of DNA repair and protection (MLH1, MGMT,
and GSTP1), cell cycle regulation (p14,15,16, and cox2), cell adherence and metastasis (E-
cadherin, bcl-2, and p73)[222-225]. However, the relationship between EBV-positive gastric
cancer and MSI is not clear because some studies reported that EBV-positive gastric carcino‐
mas presented with MSI-high but others showed no MSI in EBV-positive gastric carcinomas
[212, 226-228]. Recently, Park et al reported that in multiple gastric carcinomas, EBV infec‐
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tion allows the gastric mucosa to escape from aberrant methylation of MLH1 and induces a
malignant pathway independent of MSI [229].
Human telomerase reverse transcriptase (hTERT) is an important determinant of telomerase
activity, the enzyme that catalyses the telomere DNA synthesis [230]. It has been reported
that the majority of intestinal type gastric carcinomas have shortened telomere length, high
levels of telomerase activity and a significant expression of hTERT [231, 232].
5.6. Molecular targeted therapies and related molecular changes
Therapeutic response and prognosis may be highly variable in patients with AGC within the
same stage and chemotherapy regimens. Considering cancer is a product of accumulated
genetic aberrations, elucidation of complex biological mechanism of cancer results in devel‐
oping new molecular markers that would be specific for only tumor cells. Molecules that are
closely associated with cell proliferation, invasion, and metastasis have been studied as po‐
tential candidates for targeted therapy. In gastric and GEJ carcinomas, some candidate mole‐
cules for targeted therapy such as epidermal growth factor (EGFR), vascular endothelial
growth factor (VEGF), and P13K/AKT/mTOR pathway, as well as insulin-like growth factor
receptor (IGFR), MET pathways, and FGFR have been actively investigated [179]. Two mo‐
lecular target agents approached to phase III clinical trial are EGFR and VEGF inhibitors.
HER2 (c-erbB2) protooncogene is located on chromosome 17q11.2-12 and encodes a tyrosine
kinase receptor that is overexpressed in several types of cancer, including gastric and breast
cancers [233]. The HER family proteins regulate cell growth, survival, adhesion, migration,
and differentiation, which can be amplified or weakened in tumor cells. It has been reported
that HER2 gene amplification and/or protein overexpression in 13% to 23% of gastric and
GEJ carcinoma [234-237]. HER2 overexpression is strongly associated with poor clinical out‐
come and disease aggressiveness [238-241]. Recently, the ToGA trial which compared trastu‐
zumab plus chemotherapy vs. chemotherapy alone in patients with HER2-positive AGCs,
mostly AGCs and GEJ cancers, [234] demonstrated that adding trastuzumab to the conven‐
tional chemotherapy is therapeutically superior in patients with HER2- positive AGCs than
chemotherapy alone group.
Lapatinib is another HER2 targeted agent which is a dual tyrosine kinase inhibitor of EGFR
and HER2. It has been actively investigated as a candidate agent for patients with trastuzu‐
mab-resistant gastric and GEJ cancers [242].
VEGF is a signal protein produced by cells that plays a key role in angiogenesis within a
tumor  and increases  microvascular  permeability  [243].  It  has  been  well  known that  tu‐
mors  cannot  grow beyond a  certain  limited size  if  it  does  not  have an adequate  blood
supply. Tumors produce and secret VEGF and related receptors to enhance neovasculari‐
zation.  Increased  expression  of  VEGF  has  been  found  in  approximately  43%  of  gastric
cancers  and  is  associated  with  advanced  stage,  a  higher  risk  of  recurrence,  and  poor
prognosis  [244].  Karayiannakis  et  al  reported  that  the  serum  VEGF  concentration  is
strongly  associated  with  metastasis  and  poor  prognosis  in  patients  of  gastric  and  GEJ
carcinomas [245]. These data have shown that VEGF would be a good molecular marker
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which can be detected not only from tumor tissue but also from serum. The recently in‐
troduced  and  evaluated  anti-VEGF  therapy  are  composed  of  the  monoclonal  antibody,
bevacizumab, and multitargeted tyrosine kinase inhibitors,  sunitinib and sorafenib [242].
Bevacizumab is  a  combinant  humanized monoclonal  antibody that  targets  VEGF.  Previ‐
ous studies have shown that a combination therapy with bevacizumab and chemothera‐
py significantly enhances the efficacy of chemotherapy in colorectal,  lung, and renal cell
carcinoma as well as recurrent glioblastoma [246-249]. The first phase III study of bevaci‐
zumab (generic  name,  avastin),  the  Avastin  in  Gastric  Cancer  (AVAGAST) trial,  was to
evaluate the therapeutic efficacy of bevacizumab combined with chemotherapy (capecita‐
bine plus cisplatin) vs. chemotherapy alone as a first line therapy in patients with unre‐
sectable  AGCs  [250].  Although  AVAGAST  trial  did  not  get  a  satisfying  result  with  no
significant  difference  in  overall  survival,  however,  both  progression-free  survival  and
overall  response  rate  were  improved  in  some  patients  treated  with  bevacizumab  com‐
pared to the placebo control group. Although this strategy has demonstrated delayed tu‐
mor  progression  in  some patients,  the  results  are  more  modest  than  predicted.  Several
mechanisms of  resistance have been recently proposed and emerging evidence indicates
that,  under  certain  experimental  conditions,  antiangiogenic  agents  increase  intratumoral
hypoxia by promoting vessel pruning and inhibiting neoangiogenesis [251].
In near future, the collection and dissemination of molecular targeted therapy research in
gastric cancer will provide insight into the molecular understanding of gastric carcinogene‐
sis and interconnectedness of biological processes and allow rapid correlation with clinical
data, accelerating the impact on gastric cancer diagnosis, prognostication and treatment.
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